FIGURE 2.

p300 promotes FOXO3 to inhibit apoptosis of NPCs. (a) FOXO3 expression in clinical NP tissues of healthy controls and patients with IDD as determined by RT‐qPCR. n = 58. *** p < 0.001 vs. healthy controls. (b) FOXO3 protein expression in clinical NP tissues of healthy controls and patients with IDD as determined by Western blot assay. ** p < 0.01 vs. healthy controls. (c) FOXO3 expression in human NPCs as determined by RT‐qPCR. (d) The protein expression of FOXO3 in NPCs as determined by Western blot assay. (e) The number of proliferating cells in cultured NPCs as observed by EdU assay, green fluorescence represents EdU positive staining and blue fluorescence represents DAPI (scale bar: 25 μm). (f) The proportion of apoptotic cells in cultured NPCs. (g) FOXO3 expression in NPCs after inhibition of p300 by C646. *** p < 0.001 vs. DMSO. (h) The protein expression of FOXO3 and p300 in NPCs treated with si‐p300 as determined by Western blot assay. (i) Pearson's correlation analysis on the correlation between the expression of p300 and FOXO3 in IVD tissues of IDD patients. The measurement data were expressed as mean ± standard deviation. * p < 0.05. ** p < 0.01. *** p < 0.001. **** p < 0.0001. Comparison between two groups was conducted using independent sample t‐test. Comparison among multiple groups was conducted using one‐way ANOVA, followed by Tukey post‐hoc test